JPMorgan said Eli Lilly is enrolling about 500,000 new obesity drug patients per month, and maintains more than 60% share in ...

Eli Lilly (NYSE:LLY) drew attention on Friday after JPMorgan reiterated its bullish stance on the stock, raising its price ...

Novo Nordisk NVO generates most of its revenues from the sales of its blockbuster GLP-1 injections, Ozempic for type II ...

Find insight on Novo Nordisk, European drug exports, and more in the latest Market Talks covering Health Care.

Over half of large US employers plan to cut health benefits in 2026 as rising costs of weight-loss drugs like Wegovy drive up ...

People who take GLP-1 drugs like Ozempic can lose weight even if they face disruptions in accessing the medications, which ...

NEW YORK >> More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from ...

More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from weight-loss and ...

While some employers have covered GLP-1s hoping for long-term health savings, rising prices are forcing a rethink: "Some ...

The Market Access for CNS Therapeutics Summit is the only dedicated forum focused on tackling the unique commercial and ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. The ...